Patents by Inventor Andrew B. Ward

Andrew B. Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEQUENCING POLYCLONAL ANTIBODIES DIRECTLY FROM SINGLE PARTICLE CRYOEM DATA
    Publication number: 20240136019
    Abstract: Provided herein are methods for discovery of epitope specific monoclonal antibodies to pathogens directly from immune sera for immunotherapeutic use. Further provided herein are methods to determine molecular structure of antibodies targeting an antigen from convalescent or vaccinated individuals for the purpose of rational vaccine design.
    Type: Application
    Filed: February 24, 2022
    Publication date: April 25, 2024
    Inventors: Andrew B. Ward, Aleksandar Antanasijevic, Charles Bowman, Christopher Cottrell, Gabriel Ozorowski, Robert Kirchdoerfer
  • COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
    Publication number: 20240083954
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 14, 2024
    Inventors: Leopold Kong, Ian A. Wilson, Natalia de Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
    Patent number: 11767347
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 26, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20220098244
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • EPITOPE MAPPING METHOD
    Publication number: 20220084624
    Abstract: Provided herein are methods for mapping immune response to an immunogen, comprising: immunizing a subject with an immunogen and obtaining sera from the immunized subject at multiple time intervals following immunization, wherein the sera comprises one or more immune complexes between the immunogen and serum antibodies; imaging, by electron microscopy, the sera obtained from the immunized subject in each of the time intervals, to obtain structural images of the one or more immune complexes formed between the immunogen and serum antibodies; mapping immune response to the immunogen by measuring differences in structural images obtained at different time intervals to simultaneously visualize diverse antibodies targeting distinct epitopes in the immunized subjects.
    Type: Application
    Filed: November 29, 2021
    Publication date: March 17, 2022
    Applicant: The Scripps Research Institute
    Inventors: Lars Hangartner, Andrew B. Ward, Matteo Bianchi, Hannah Turner
  • Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
    Patent number: 11236134
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 1, 2022
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20200165303
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 28, 2020
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
    Patent number: 10647748
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 12, 2020
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20190048043
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 14, 2019
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu